RBC
NVO

Rye Brook Capital’s Novo Nordisk NVO Stock Holding History

Rye Brook Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
+6,500
New +$279K 0.22% 33

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

Rye Brook Capital's NVO Position: Q2 2026 in Review

Rye Brook Capital opened a new position in Novo Nordisk (NVO) in Q2 2026: 6,500 shares worth $312K. The stake represents 0.22% of the portfolio and ranks #33 among its holdings.

884 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Rye Brook Capital held 6,500 shares of Novo Nordisk worth $312K as of Q2 2026.
  • Novo Nordisk was a new Rye Brook Capital position in Q2 2026.
  • Novo Nordisk made up 0.22% of Rye Brook Capital's portfolio in Q2 2026, its #33 holding.
  • 884 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Rye Brook Capital's 13F filing for Q2 2026, filed 20 Jul 2026.